Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Global Forecast to 2029
The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period. Factors such as the increasing im... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryThe global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period. Factors such as the increasing importance of companion diagnostics in drug development, rising cancer incidence, and the growing adoption of targeted therapies are driving market growth.“The assays, reagents & kits segment expected to achieve the highest growth rate in the companion diagnostics market, by product & service, during the forecast period” The companion diagnostics market is categorized into assays, kits & reagents, instruments/systems and software & services based on product & service. In 2023, the assays, kits & reagents segment held the largest share of the market. This can be attributed to factors such as the wide range of available products, the rising utilization of assays and kits across various therapeutic fields, and the increasing demand for these products in both basic research and commercial applications. “Pharmaceutical & biotechnology companies segment projected to account for the highest CAGR during the forecast period” Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users. In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market. This notable position is primarily attributed to the increasing adoption of companion diagnostics in drug development and the growing significance of companion diagnostic biomarkers. Furthermore, the rising interest in personalized medicine, along with the pressing need for targeted therapies across various diseases and disorders, is forecasted to boost the demand and integration of companion diagnostics among pharmaceutical & biotechnology companies. “Asia Pacific: The fastest-growing region in companion diagnostics care market” The global companion diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, Middle East & Africa and the GCC Countries. The Asia Pacific region is expected to record the highest CAGR during the forecast period. This growth is attributed to factors such as increased healthcare expenditure, rising pharmaceutical research funding, government initiatives to raise awareness about early disease detection, expansion of private-sector hospitals into rural areas in various APAC countries, and the presence of high-growth markets in the region. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 -35% • By Designation: C-level - 30%, D-level - 20%, and Others - 50% • By Region: North America - 42%, Europe - 31%, Asia Pacific - 20%, and Rest of the World -7% Lists of Companies Profiled in the Report: • F. Hoffmann-La Roche Ltd (Switzerland) • Agilent Technologies, Inc. (US) • QIAGEN (Netherlands) • Thermo Fisher Scientific Inc. (US) • Abbott (US) • Almac Group (UK) • Danaher (US • Illumina, Inc. (US) • bioMérieux (France) • Myriad Genetics, Inc. (US) • Sysmex Corporation (Japan) • ARUP Laboratories (UK) • Abnova Corporation (Taiwan) • Guardant Health (US) • ICON Plc (Ireland) • BioGenex (US) • Invivoscribe, Inc. (US) • ArcherDX, Inc. (Integrated DNA Technologies, Inc.) (US) • NG Biotech (France) • Q² Solutions (US) • Amoy Diagnostics Co., Ltd. (China) • Uniogen (Abacus Diagnostica) (Finland) • Asuragen, Inc. (Bio-Techne) (US) • NG Biotech (France) • Meso Scale Diagnostics, LLC. (US) • Creative Biolabs (US) Research Coverage: This research report categorizes the companion diagnostics market by products, type, application and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies; contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the companion diagnostics market. Competitive analysis of upcoming startups in the companion diagnostics market ecosystem is covered in this report. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the companion diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the companion diagnostics market. • Market Development: Comprehensive information about lucrative markets – the report analyses the companion diagnostics market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the companion diagnostics market. • Competitive Assessment: In-depth assessment of market ranking, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US) and Abbott (US). Table of Contents1 INTRODUCTION 461.1 STUDY OBJECTIVES 46 1.2 MARKET DEFINITION 46 1.2.1 INCLUSIONS & EXCLUSIONS 47 1.3 MARKET SEGMENTATION 48 1.3.1 MARKETS COVERED 48 1.3.2 REGIONS COVERED 49 1.3.3 YEARS CONSIDERED 49 1.4 CURRENCY CONSIDERED 50 1.5 RESEARCH LIMITATIONS 50 1.6 MARKET STAKEHOLDERS 50 1.7 SUMMARY OF CHANGES 51 1.7.1 RECESSION IMPACT 51 2 RESEARCH METHODOLOGY 52 2.1 RESEARCH DATA 52 2.2 RESEARCH APPROACH 52 FIGURE 1 RESEARCH DESIGN METHODOLOGY 52 2.2.1 SECONDARY DATA 53 2.2.1.1 Key data from secondary sources 54 2.2.2 PRIMARY DATA 55 2.2.2.1 Primary sources 55 2.2.2.2 Key data from primary sources 56 2.2.2.3 Key industry insights 57 2.2.2.4 Breakdown of primary interviews 57 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 57 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 58 2.3 MARKET SIZE ESTIMATION 58 2.3.1 BOTTOM-UP APPROACH 59 2.3.1.1 Approach 1: Company revenue estimation approach 59 FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 59 2.3.1.2 Approach 2: Presentations of companies and primary interviews 59 2.3.1.3 Growth forecast 60 2.3.1.4 CAGR projections 60 FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 60 2.3.2 TOP-DOWN APPROACH 60 FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH 61 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 62 FIGURE 7 DATA TRIANGULATION METHODOLOGY 62 2.5 STUDY ASSUMPTIONS 63 2.6 GROWTH RATE ASSUMPTIONS 63 2.7 LIMITATIONS 63 2.8 RISK ASSESSMENT 64 2.8.1 RISK ASSESSMENT ANALYSIS 64 2.9 RECESSION IMPACT ANALYSIS 64 3 EXECUTIVE SUMMARY 66 FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 66 FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 67 FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 68 FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION) 69 FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 69 FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 70 4 PREMIUM INSIGHTS 71 4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 71 FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 71 4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2024 VS. 2029 71 FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029 71 4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029 72 FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 72 4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2024 VS. 2029 72 FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 72 4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY SAMPLE TYPE, 2024 VS. 2029 73 FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 73 4.6 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 73 FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029 73 4.7 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74 FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD 74 5 MARKET OVERVIEW 75 5.1 INTRODUCTION 75 5.2 MARKET DYNAMICS 75 FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75 5.2.1 DRIVERS 76 5.2.1.1 Ability of CDx tests to reduce healthcare costs and increase efficiency 76 5.2.1.2 Growing focus on targeted therapy 76 5.2.1.3 Rising demand for personalized medicine 77 FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015−2022) 77 5.2.1.4 Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine 78 FIGURE 23 GLOBAL CANCER INCIDENCE (2008−2030) 78 TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0–85+), 2022 VS. 2045 79 5.2.1.5 Growing application areas for companion diagnostics 79 5.2.2 RESTRAINTS 79 5.2.2.1 Significant capital investment and low cost-benefit ratio 79 5.2.2.2 High cost of companion diagnostic tests 80 5.2.2.3 Unfavorable reimbursements 80 TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS 81 5.2.2.4 High cost of immunotherapy treatment 81 5.2.3 OPPORTUNITIES 82 5.2.3.1 Increasing demand for next-generation sequencing 82 TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS 82 5.2.3.2 Growing significance of companion diagnostics in drug development 83 TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS 83 5.2.3.3 Advancements in genomics research and rising clinical trials 83 5.2.4 CHALLENGES 84 5.2.4.1 Shortage of healthcare professionals 84 5.2.4.2 Limited awareness in emerging markets 84 5.3 PRICING ANALYSIS 85 TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS 85 TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION 85 5.4 PATENT ANALYSIS 86 FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014–DECEMBER 2023) 86 5.5 TRADE ANALYSIS 87 5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 87 TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION) 87 TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION) 87 5.6 VALUE CHAIN ANALYSIS 87 FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES 88 5.7 SUPPLY CHAIN ANALYSIS 89 FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 89 5.8 ECOSYSTEM ANALYSIS 90 FIGURE 27 ECOSYSTEM MAP 90 TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 90 5.9 PORTER’S FIVE FORCES ANALYSIS 91 TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 91 5.9.1 THREAT OF NEW ENTRANTS 91 5.9.2 THREAT OF SUBSTITUTES 91 5.9.3 BARGAINING POWER OF BUYERS 91 5.9.4 BARGAINING POWER OF SUPPLIERS 92 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 92 5.10 REGULATORY LANDSCAPE 92 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 5.10.2 NORTH AMERICA 94 5.10.2.1 US 94 5.10.2.2 Canada 94 5.10.3 EUROPE 94 TABLE 15 EUROPE: CLASSIFICATION OF DEVICES 95 5.10.4 ASIA PACIFIC 95 5.10.4.1 China 95 5.10.4.2 Japan 95 TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96 5.10.4.3 India 96 5.10.5 LATIN AMERICA 96 5.10.5.1 Brazil 96 5.10.5.2 Mexico 97 5.10.6 MIDDLE EAST 97 5.10.7 AFRICA 97 5.11 TECHNOLOGY ANALYSIS 97 5.11.1 KEY TECHNOLOGIES 98 5.11.1.1 Polymerase chain reaction (PCR) 98 5.11.1.2 Next-generation sequencing (NGS) 98 5.11.2 COMPLIMENTARY TECHNOLOGIES 98 5.11.2.1 In situ hybridization (ISH) 98 5.11.3 ADJACENT TECHNOLOGIES 98 5.11.3.1 Immunohistochemistry (IHC) 98 5.12 KEY CONFERENCES & EVENTS IN 2024–2025 99 TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 99 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100 5.13.1 REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET 100 FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET 100 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS 101 TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%) 101 5.14.2 BUYING CRITERIA 102 FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS 102 TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS 102 5.15 INVESTMENT AND FUNDING SCENARIO 103 FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO 103 6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 104 6.1 INTRODUCTION 105 TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 105 6.2 ASSAYS, KITS, AND REAGENTS 105 6.2.1 INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS 105 TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY 106 TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022–2029 (USD MILLION) 107 TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 107 TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 108 TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 108 TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 109 6.3 INSTRUMENTS & SYSTEMS 109 6.3.1 LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH 109 TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY 110 TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022–2029 (USD MILLION) 110 TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 111 TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 111 TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 112 TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 112 6.4 SOFTWARE & SERVICES 112 6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH 112 TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY 113 TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2029 (USD MILLION) 113 TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 114 TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION 114 TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 115 TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 115 7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 116 7.1 INTRODUCTION 117 TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 117 7.2 POLYMERASE CHAIN REACTION 117 7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH 117 TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION 118 TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE 118 TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION) 119 TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 119 TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 120 TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 120 TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 121 7.3 IN SITU HYBRIDIZATION 121 7.3.1 INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH 121 TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE 122 TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION) 122 TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 123 TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 123 TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124 TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124 7.4 NEXT-GENERATION SEQUENCING 124 7.4.1 ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH 124 TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE 125 TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 126 TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 126 TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127 TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127 TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 128 7.5 IMMUNOHISTOCHEMISTRY 128 7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH 128 TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE 129 TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION) 129 TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 130 TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 130 TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 131 TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 131 7.6 OTHER TECHNOLOGIES 131 TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 132 TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 132 TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133 TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133 TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 134 8 COMPANION DIAGNOSTICS MARKET, BY INDICATION 135 8.1 INTRODUCTION 136 TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 136 8.2 CANCER 136 TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040 137 TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 137 TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 137 TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 138 TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 138 TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 139 TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 139 8.2.1 LUNG CANCER 139 8.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption 139 TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 140 TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION) 141 TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 141 TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 142 TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 142 TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 143 8.2.2 BREAST CANCER 143 8.2.2.1 Wide prevalence of breast cancer to boost market growth 143 TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 144 TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION) 144 TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 144 TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145 TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145 TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 146 8.2.3 BLOOD CANCER 146 8.2.3.1 Growing incidence of blood cancer to drive market 146 TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040 147 TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022–2029 (USD MILLION) 147 TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 147 TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148 TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148 TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 149 8.2.4 COLORECTAL CANCER 149 8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth 149 TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040 150 TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION) 150 TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 150 TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151 TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151 TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 152 8.2.5 OTHER CANCERS 152 TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION) 152 TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153 TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153 TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 154 TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 154 8.3 NEUROLOGICAL DISEASES 154 8.3.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS 154 TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 155 TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 155 TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 156 TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 156 TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 157 8.4 CARDIOVASCULAR DISEASES 157 8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH 157 TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION) 158 TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 158 TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 159 TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 159 TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 160 8.5 INFECTIOUS DISEASES 160 8.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH 160 TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 161 TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 161 TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162 TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162 TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 163 8.6 OTHER INDICATIONS 163 TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 163 TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164 TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164 TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165 TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165 9 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE 166 9.1 INTRODUCTION 167 TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 167 9.2 TISSUE SAMPLES 167 9.2.1 COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET 167 TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS 168 TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022–2029 (USD MILLION) 168 TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 169 TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 169 TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 170 TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 170 9.3 BLOOD SAMPLES 170 9.3.1 LESS INVASIVE METHOD—KEY FACTOR DRIVING ADOPTION 170 TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS 171 TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION) 171 TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 172 TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 172 TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 173 TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 173 9.4 OTHER SAMPLE TYPES 173 TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS 174 TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION) 174 TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 174 TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 175 TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 175 TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 176 10 COMPANION DIAGNOSTICS MARKET, BY END USER 177 10.1 INTRODUCTION 178 TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 178 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 178 10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET 178 TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 179 TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 179 TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 180 TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 180 TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 181 10.3 REFERENCE LABORATORIES 181 10.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH 181 TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 182 TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 182 TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 183 TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 183 TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 184 10.4 CONTRACT RESEARCH ORGANIZATIONS 184 10.4.1 RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH 184 TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 185 TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 185 TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 186 TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 186 TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 187 10.5 OTHER END USERS 187 TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 188 TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 188 TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 189 TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 189 TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 190 11 COMPANION DIAGNOSTICS MARKET, BY REGION 191 11.1 INTRODUCTION 192 TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 192 11.2 NORTH AMERICA 192 TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045 193 FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT 194 TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 194 TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 195 TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 195 TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 196 TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 196 TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 197 TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 197 11.2.1 NORTH AMERICA: RECESSION IMPACT 197 11.2.2 US 198 11.2.2.1 Increasing use of companion diagnostics for cancer treatment to boost market growth 198 TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 199 TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 199 TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 199 TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 200 TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 200 TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 201 TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 201 11.2.3 CANADA 201 11.2.3.1 Increasing government initiatives to drive market 201 TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 202 TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 203 TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 203 TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 204 TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 204 TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 205 TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 205 11.3 EUROPE 205 TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206 TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 207 TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 207 TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 208 TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 208 TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 209 TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 209 11.3.1 EUROPE: RECESSION IMPACT 209 11.3.2 GERMANY 210 11.3.2.1 Increasing healthcare expenditure to drive market 210 TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 211 TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 211 TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 212 TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 212 TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 213 TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 213 11.3.3 UK 213 11.3.3.1 Growing life science industry and increasing focus on research to propel market 213 TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 214 TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 215 TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 215 TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 216 TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 216 TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 217 11.3.4 SWITZERLAND 217 11.3.4.1 Strong research-oriented pharma industry to support market growth 217 TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 218 TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 218 TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 219 TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 219 TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 220 TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 220 11.3.5 FRANCE 220 11.3.5.1 Increasing government funding for research to support market growth 220 TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 221 TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 222 TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 222 TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 223 TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 223 TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 224
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社のMedical Devices分野での最新刊レポート
本レポートと同じKEY WORD(blood)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |